86044-63-5 Usage
Molecular weight
296.33 g/mol
Chemical structure
2-[[E-(3-methoxy-4-oxo-1-cyclohexa-2,5-dienylidene)methyl]amino]guanidine, also known as MOCHDA
Type of compound
Guanidine derivative
Potential applications
Medicine and pharmacology, specifically as an anti-cancer agent, anti-inflammatory, and anti-bacterial agent, as well as in the treatment of neurodegenerative diseases.
Mechanism of action
Not fully understood, but has been studied for its ability to inhibit the growth of cancer cells and its potential anti-inflammatory and anti-bacterial properties.
Additional information
Further research is needed to fully understand the potential uses and mechanisms of action of 2-[[E-(3-methoxy-4-oxo-1-cyclohexa-2,5-dienylidene)methyl]amino]guanidine.
Check Digit Verification of cas no
The CAS Registry Mumber 86044-63-5 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 8,6,0,4 and 4 respectively; the second part has 2 digits, 6 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 86044-63:
(7*8)+(6*6)+(5*0)+(4*4)+(3*4)+(2*6)+(1*3)=135
135 % 10 = 5
So 86044-63-5 is a valid CAS Registry Number.
86044-63-5Relevant articles and documents
Synthesis, Antileishmanial Activity and In Silico Studies of Aminoguanidine Hydrazones (AGH) and Thiosemicarbazones (TSC) Against Leishmania chagasi Amastigotes
Alexandre-Moreira, Magna S.,Aquino, Pedro G. V.,Bourguignon, Jean-Jacques,Bri-Card, Jacques,Freitas, Johnnatan D.,Meneghetti, Mario R.,Nascimento, Igor J. S.,Queiroz, Aline C.,Rodrigues, Klinger A. F.,Rodrigues, Raiza R. L.,Santos, Mariana S.,Schmitt, Martine,de Aquino, Thiago M.,Araújo, Morgana V.,Fran?a, Paulo H. B.,Rodrigues, érica E. E. S.,Santos-Júnior, Paulo F. S.,da Silva-Júnior, Edeildo F.,de Araújo-Júnior, Jo?o X.
, p. 151 - 169 (2022/02/05)
Background: Leishmaniasis is a worldwide health problem, highly endemic in developing countries. Among the four main clinical forms of the disease, visceral leishmaniasis is the most se-vere, fatal in 95% of cases. The undesired side-effects from first-li
